Last reviewed · How we verify
cardio-selective beta blocker group
Blocks beta-1 adrenergic receptors to reduce heart rate and blood pressure.
Blocks beta-1 adrenergic receptors to reduce heart rate and blood pressure. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | cardio-selective beta blocker group |
|---|---|
| Also known as | concor |
| Sponsor | Sherief Abd-Elsalam |
| Drug class | Cardio-selective beta blocker |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Cardio-selective beta blockers, like this drug, primarily target beta-1 receptors in the heart, reducing heart rate and blood pressure without significantly affecting beta-2 receptors in the lungs. This leads to a decrease in myocardial oxygen demand and a reduction in the risk of cardiovascular events.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Bradycardia
- Fatigue
- Dizziness
Key clinical trials
- Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis (PHASE3)
- Use of Beta-blockers and Risk of New Onset Diabetes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cardio-selective beta blocker group CI brief — competitive landscape report
- cardio-selective beta blocker group updates RSS · CI watch RSS
- Sherief Abd-Elsalam portfolio CI